Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia

Background/Aim. Intravenous immunoglobulin is a blood product made of human polyclonal immunoglobulin G. The mode of action of intravenous immunoglobulin is very complex. It is indicated in treatment of neonatal immune thrombocytopenia and haemolytic disease of the newborn. The aim of the study...

Full description

Saved in:
Bibliographic Details
Main Authors: Marković-Sovtić Gordana, Janković Borisav, Rakonjac Zorica, Martić Jelena, Pejić Katarina
Format: Article
Language:English
Published: Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade 2013-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501311029M.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850247566857338880
author Marković-Sovtić Gordana
Janković Borisav
Rakonjac Zorica
Martić Jelena
Pejić Katarina
author_facet Marković-Sovtić Gordana
Janković Borisav
Rakonjac Zorica
Martić Jelena
Pejić Katarina
author_sort Marković-Sovtić Gordana
collection DOAJ
description Background/Aim. Intravenous immunoglobulin is a blood product made of human polyclonal immunoglobulin G. The mode of action of intravenous immunoglobulin is very complex. It is indicated in treatment of neonatal immune thrombocytopenia and haemolytic disease of the newborn. The aim of the study was to present our experience in the use of intravenous immunoglobulin in a group of term neonates. Methods. We analysed all relevant clinical and laboratory data of 23 neonates who recieved intravenous immunoglobulin during their hospitalization in Neonatal Intensive Care Unit of Mother and Child Health Care Institute over a five year period, from 2006. to 2010. Results. There were 11 patients with haemolytic disease of the newborn and 12 neonates with immune thrombocytopenia. All of them recieved 1-2 g/kg intravenous immunoglobulin in the course of their treatment. There was no adverse effects of intravenous immunoglobulin use. The use of intravenous immunoglobulin led to an increase in platelet number in thrombocytopenic patients, whereas in those with haemolytic disease serum bilirubin level decreased significantly, so that some patients whose bilirubin level was very close to the exchange transfusion criterion, avoided this procedure. Conclusion. The use of intravenous immunoglobulin was shown to be an effective treatment in reducing the need for exchange transfusion, duration of phototherapy and the length of hospital stay in neonates with haemolytic disease. When used in treatment of neonatal immune thrombocytopenia, it leads to an increase in the platelet number, thus decreasing the risk of serious complications of thrombocytopenia.
format Article
id doaj-art-046c5a4f98cf41da8e5afb2de9c0d24d
institution OA Journals
issn 0042-8450
language English
publishDate 2013-01-01
publisher Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
record_format Article
series Vojnosanitetski Pregled
spelling doaj-art-046c5a4f98cf41da8e5afb2de9c0d24d2025-08-20T01:58:54ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502013-01-0170111029103310.2298/VSP1311029MUse of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopeniaMarković-Sovtić GordanaJanković BorisavRakonjac ZoricaMartić JelenaPejić KatarinaBackground/Aim. Intravenous immunoglobulin is a blood product made of human polyclonal immunoglobulin G. The mode of action of intravenous immunoglobulin is very complex. It is indicated in treatment of neonatal immune thrombocytopenia and haemolytic disease of the newborn. The aim of the study was to present our experience in the use of intravenous immunoglobulin in a group of term neonates. Methods. We analysed all relevant clinical and laboratory data of 23 neonates who recieved intravenous immunoglobulin during their hospitalization in Neonatal Intensive Care Unit of Mother and Child Health Care Institute over a five year period, from 2006. to 2010. Results. There were 11 patients with haemolytic disease of the newborn and 12 neonates with immune thrombocytopenia. All of them recieved 1-2 g/kg intravenous immunoglobulin in the course of their treatment. There was no adverse effects of intravenous immunoglobulin use. The use of intravenous immunoglobulin led to an increase in platelet number in thrombocytopenic patients, whereas in those with haemolytic disease serum bilirubin level decreased significantly, so that some patients whose bilirubin level was very close to the exchange transfusion criterion, avoided this procedure. Conclusion. The use of intravenous immunoglobulin was shown to be an effective treatment in reducing the need for exchange transfusion, duration of phototherapy and the length of hospital stay in neonates with haemolytic disease. When used in treatment of neonatal immune thrombocytopenia, it leads to an increase in the platelet number, thus decreasing the risk of serious complications of thrombocytopenia.http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501311029M.pdfthrombocytopenia, neonatal alloimmuneanemia, hemolyticinfant, newbornimmunoglobulins, intravenous
spellingShingle Marković-Sovtić Gordana
Janković Borisav
Rakonjac Zorica
Martić Jelena
Pejić Katarina
Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
Vojnosanitetski Pregled
thrombocytopenia, neonatal alloimmune
anemia, hemolytic
infant, newborn
immunoglobulins, intravenous
title Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
title_full Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
title_fullStr Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
title_full_unstemmed Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
title_short Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
title_sort use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia
topic thrombocytopenia, neonatal alloimmune
anemia, hemolytic
infant, newborn
immunoglobulins, intravenous
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501311029M.pdf
work_keys_str_mv AT markovicsovticgordana useofintravenousimmunoglobulininneonateswithhaemolyticdiseaseandimmunethrombocytopenia
AT jankovicborisav useofintravenousimmunoglobulininneonateswithhaemolyticdiseaseandimmunethrombocytopenia
AT rakonjaczorica useofintravenousimmunoglobulininneonateswithhaemolyticdiseaseandimmunethrombocytopenia
AT marticjelena useofintravenousimmunoglobulininneonateswithhaemolyticdiseaseandimmunethrombocytopenia
AT pejickatarina useofintravenousimmunoglobulininneonateswithhaemolyticdiseaseandimmunethrombocytopenia